심혈관 분야의 제휴 및 라이선스 계약(2016-2026년)

Understand the cardiovascular partnering landscape using intelligence from 664 real-world collaboration and licensing deals.

Cardiovascular Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 664 partnering deals involving cardiovascular assets, technologies and development programs.

Cardiovascular partnering spans a diverse range of therapeutic indications, technologies and stages of development, from early research collaborations through to licensing and commercialization agreements.

The report brings this activity together in one resource, enabling users to understand who is partnering, which cardiovascular opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, individual transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in cardiovascular partnering.

Understand the cardiovascular partnering landscape

The report analyzes cardiovascular dealmaking from 2016 to 2026, including:

• Trends in cardiovascular partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Cardiovascular therapeutic indication
• Most active cardiovascular dealmakers
• Leading deals by disclosed value
• How cardiovascular partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark cardiovascular deal financials
• Financial terms can vary considerably according to the nature of the cardiovascular asset, development stage, technology, rights granted and transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can then investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment and deal preparation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading cardiovascular dealmakers and prospective partners
• The report identifies the most active companies in cardiovascular partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking cardiovascular opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in particular cardiovascular indications
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in specific technologies or approaches
• Competitors pursuing similar external innovation strategies
• For companies seeking to partner a cardiovascular asset or technology, previous transaction activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across cardiovascular indications
• Cardiovascular disease encompasses multiple distinct therapeutic areas and development strategies.
• The report analyzes deals by cardiovascular therapeutic indication, allowing users to move beyond broad market-level benchmarks and investigate the transactions most relevant to a particular program or area of strategic interest.
• Combined with analysis by technology and development stage, this enables users to develop a more focused view of comparable deal activity.
• Understand how cardiovascular agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for a cardiovascular partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected cardiovascular transactions.

These agreements can provide significantly more detail than headline announcements alone, helping users examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating a cardiovascular collaboration or licensing agreement, real contract language provides valuable insight into how comparable transactions have been structured in practice.
• Comprehensive cardiovascular deal directory
• The report includes a comprehensive directory of 664 cardiovascular collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable cardiovascular deals, prospective partners and relevant transaction structures.
• Search and Evaluation teams
• Understand which companies are actively seeking cardiovascular opportunities across particular indications, technologies and stages of development.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable cardiovascular assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building cardiovascular pipelines through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide cardiovascular intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying cardiovascular deal intelligence to the customer's own asset, technology, indication or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

• 2.1. Introduction
• 2.2. Cardiovascular partnering over the years
• 2.3. Cardiovascular partnering by deal type
• 2.4. Cardiovascular partnering by industry sector
• 2.5. Cardiovascular partnering by stage of development
• 2.6. Cardiovascular partnering by technology type
• 2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 - Financial deal terms for cardiovascular partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for cardiovascular partnering
• 3.3. Cardiovascular partnering headline values
• 3.4. Cardiovascular deal upfront payments
• 3.5. Cardiovascular deal milestone payments
• 3.6. Cardiovascular royalty rates

Chapter 4 - Leading cardiovascular deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in cardiovascular partnering
• 4.3. List of most active dealmakers in cardiovascular
• 4.4. Top cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory

• 5.1. Introduction
• 5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by cardiovascular therapeutic target
• Deal directory
• Deal directory - Cardiovascular deals by company A-Z
• Deal directory - Cardiovascular deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cardiovascular partnering since 2016
• Figure 2: Cardiovascular partnering by deal type since 2016
• Figure 3: Cardiovascular partnering by industry sector since 2016
• Figure 4: Cardiovascular partnering by stage of development since 2016
• Figure 5: Cardiovascular partnering by technology type since 2016
• Figure 6: Cardiovascular partnering by indication since 2016
• Figure 7: Cardiovascular deals with a headline value
• Figure 8: Cardiovascular deals with upfront payment values
• Figure 9: Cardiovascular deals with milestone payment
• Figure 10: Cardiovascular deals with royalty rates
• Figure 11: Active cardiovascular dealmaking activity since 2016
• Figure 12: Top cardiovascular deals by value since 2016